PRR Share Price

Open 0.03 Change Price %
High 0.03 1 Day 0.00 0.00
Low 0.03 1 Week 0.00 0.00
Close 0.03 1 Month -0.01 -25.00
Volume 382625 1 Year -0.01 -25.00
52 Week High 0.05
52 Week Low 0.03
PRR Important Levels
Resistance 2 0.03
Resistance 1 0.03
Pivot 0.03
Support 1 0.03
Support 2 0.03
ASX Australia Most Active Stocks
BUR 0.02 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
AGO 0.03 0.00%
AGO 0.03 0.00%
AGO 0.03 0.00%
KEY 0.01 0.00%
KEY 0.01 0.00%
KEY 0.01 0.00%
KEY 0.01 0.00%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
GBG 0.03 50.00%
GBG 0.03 50.00%
GBG 0.03 50.00%
BNV 0.03 50.00%
PMQ 0.03 50.00%
ANP 0.04 33.33%
More..
ASX Australia Top Losers Stocks
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
XST 0.01 -50.00%
XST 0.01 -50.00%
GDY 0.01 -50.00%
RDS 0.02 -33.33%
RDS 0.02 -33.33%
More..

Prima Biomed Ltd (ASX: PRR)

PRR Technical Analysis 5
As on 24th Mar 2017 PRR Share Price closed @ 0.03 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.04 & Strong Sell for SHORT-TERM with Stoploss of 0.04 we also expect STOCK to react on Following IMPORTANT LEVELS.
PRR Target for March
1st Target up-side 0.04
2nd Target up-side 0.04
3rd Target up-side 0.04
1st Target down-side 0.02
2nd Target down-side 0.02
3rd Target down-side 0.02
PRR Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.primabiomed.com.au
PRR Address
PRR
151 Macquarie Street
Level 7
Sydney, NSW 2000
Australia
Phone: 61 2 9276 1224
Fax: 61 2 9276 1284
PRR Latest News
Interactive Technical Analysis Chart Prima Biomed Ltd ( PRR ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Prima Biomed Ltd
PRR Business Profile
Prima BioMed Ltd., a biotechnology company, researches, develops, and commercializes licensed medical biotechnology products in Australia. Its lead product includes CVac, a cancer vaccine for patients in remission, which has completed two human clinical trials. The company is also developing oral vaccine against human papilloma virus, a virus associated with development of cervical cancer. Prima BioMed Ltd. is based in Sydney, Australia.